Trial reportEuropean journal of endocrinology2012
Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial.
Trial report in European journal of endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 55 citations in OpenAlex.
- Growth Hormone Administration Improves Nonalcoholic Fatty Liver Disease in Overweight/Obesity: A Randomized Trial.The Journal of clinical endocrinology and metabolism · 2023Trial
- Impact of GH administration on skeletal endpoints in adults with overweight/obesity.European journal of endocrinology · 2022Trial
- Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease.BMC endocrine disorders · 2022Trial
- The effect of growth hormone on bioactive IGF in overweight/obese women.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2018Trial
- GH administration decreases subcutaneous abdominal adipocyte size in men with abdominal obesity.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2017Trial
- Effect of growth hormone on cognitive function in young women with abdominal obesity.Clinical endocrinology · 2016Trial
- Vertebral Strength and Estimated Fracture Risk Across the BMI Spectrum in Women.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2016Trial
- Trial
- Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity.The Journal of clinical endocrinology and metabolism · 2013Trial
- Effects of growth hormone withdrawal in obese premenopausal women.Clinical endocrinology · 2013Trial
- Cardiac and aerobic response to growth hormone therapy in children with short stature: a prospective study using VOFrontiers in endocrinology · 2026Article
- Growth hormone attenuates obesity and reshapes gut microbiota in high-fat diet-fed mice.Metabolism open · 2024Article
- Important Hormones Regulating Lipid Metabolism.Molecules (Basel, Switzerland) · 2022Review
- The GH/IGF-1 Axis Is Associated With Intrahepatic Lipid Content and Hepatocellular Damage in Overweight/Obesity.The Journal of clinical endocrinology and metabolism · 2022Article
- Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2022Article
- Association between muscle mass and insulin sensitivity independent of detrimental adipose depots in young adults with overweight/obesity.International journal of obesity (2005) · 2020Article
- HIV and antiretroviral therapy-related fat alterations.Nature reviews. Disease primers · 2020Review
- Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity.BioMed research international · 2020Article
- Sex differences in body composition and association with cardiometabolic risk.Biology of sex differences · 2018Article
- Effects of recombinant human growth hormone administration on cardiovascular risk factors in obese children with relative growth hormone deficiency.Lipids in health and disease · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
Abstract
objectiveAbdominal adiposity is associated with increased cardiovascular risk and decreased GH secretion. The objective of our study was to determine the effects of GH on body composition and cardiovascular risk markers in abdominally obese women. MATERIALS AND
methodsIn this randomized, double-blind, placebo-controlled study, 79 obese premenopausal women received GH vs placebo for 6 months. Primary endpoints were i) total abdominal (total abdominal adipose tissue, TAT) fat by computed tomography (CT) (body composition) and ii) high-sensitivity C-reactive protein (hsCRP) (cardiovascular risk marker). Body composition was assessed by CT, dual-energy X-ray absorptiometry, and proton MR spectroscopy. Serum cardiovascular risk markers, carotid intima-media thickness, and endothelial function were measured.
resultsMean 6-month GH dose was 1.7±0.1 mg/day, resulting in a mean IGF1 SDS increase from -1.7±0.08 to -0.1±0.3 in the GH group. GH administration decreased TAT and hsCRP compared with placebo. In addition, it increased thigh muscle mass and lean body mass and decreased subcutaneous abdominal and trunk fat, tissue plasminogen activator, apoB, and apoB/low-density lipoprotein compared with placebo. Visceral adipose tissue (VAT) decreased and intramyocellular lipid increased within the GH group. Six-month change in IGF1 levels was negatively associated with 6-month decrease in TAT and VAT. One subject had a 2 h glucose >200 mg/ml at 3 months; four subjects, three of whom were randomized to GH, had 2 h glucose levels >200 mg/ml at the end of the study.
conclusionGH administration in abdominally obese premenopausal women exerts beneficial effects on body composition and cardiovascular risk markers but is associated with a decrease in glucose tolerance in a minority of women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.